You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
遠大醫藥(00512.HK)獲滴眼液產品獨家授權
阿思達克 06-04 02:59
遠大醫藥(00512.HK)公布,近日與台新藥達成產品獨家授權協議。據此,集團將以不超過950萬美元里程碑付款及一定比例的銷售提成,獲得台新藥開發的針對眼科術後抗炎鎮痛的改良型新藥激素納米混懸滴眼液「APP13007」在中國、香港和澳門地區的獨家開發和商業化權利。

APP13007主要活性成分是一種強效的糖皮質激素,具有高效的局部抗炎活性和較強的毛細血管收縮作用,已於美國完成的II期臨床試驗顯示,產品具有良好的安全性及有效性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account